<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <title></title>
    <style type="text/css">

 p.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	}
p.MsoHeading9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	text-align:justify;
	text-indent:.5in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	font-weight:bold;
        }
p.MsoBodyText2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	}
a:link
	{color:blue;
	text-decoration:underline;
	text-underline:single;
        }
p.MsoHeader
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	tab-stops:center 3.0in right 6.0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	}
p.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	}
p.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:27.0pt;
	text-align:justify;
	text-indent:-27.0pt;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	}
p.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	}
    p.Text
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	}
p.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	}
ul
	{margin-bottom:0in;}
 li.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	}
    </style>
</head>
<body>

    <p class="MsoNormal">
        <b style="mso-bidi-font-weight:normal"><u>
        <span style="font-size:11.0pt;color:black;layout-grid-mode:line">Novartis 
        Oncology Access Program Malaysia (NOA)<o:p></o:p></span></u></b></p>
    <p class="MsoNormal">
        <span style="font-size:10.0pt;mso-bidi-font-style:italic"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt;mso-bidi-font-style:italic">Novartis Oncology 
        Access Program<i> </i>Malaysia (NOA), is a shared contribution program for new 
        patients seeking Glivec<sup>®</sup> or Tasigna<sup>®</sup> therapy. Patients 
        enrolled under this program will receive contribution towards the cost of 6 
        months of Glivec<sup>®</sup> or Tasigna<sup>®</sup> treatment per year from 
        Novartis Corporation (Malaysia) Sdn Bhd (Novartis). All Malaysian citizens are 
        eligible for NOA.<i> </i>No financial evaluation is required for all eligible 
        patients choosing to participate in NOA. </span><span style="font-size:11.0pt">
        NOA, provides sustainable access to <span style="mso-bidi-font-style:italic">
        Glivec<sup>®</sup> and Tasigna<sup>®</sup> </span>where Novartis shares the cost 
        of its medicines with patients who are unable to pay for the full cost of their 
        medication. <o:p></o:p></span>
    </p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">NOA was established to enable patients diagnosed 
        with all registered indications of Glivec<sup>® </sup>
        <span style="mso-bidi-font-style:italic">and Tasigna<sup>®</sup>. <o:p></o:p>
        </span></span>
    </p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt;mso-bidi-font-style:italic">The full registered 
        indication of </span><span style="font-size:11.0pt">Glivec<sup>® </sup>is as 
        below: <o:p></o:p></span>
    </p>
    <p align="left" class="Text" style="margin-left:.5in;text-align:left;text-indent:
-.25in;mso-list:l4 level1 lfo4">
        <![if !supportLists]>
        <span lang="X-NONE" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]>
        <span lang="X-NONE" style="font-size:11.0pt;
font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">adult and pediatric patients with 
        newly diagnosed chronic myeloid leukaemia (CML) as well as for the treatment of 
        adult and pediatric patients with CML in blast crisis, accelerated phase, or in 
        chronic phase after failure of interferon-alpha therapy.<o:p></o:p></span></p>
    <p align="left" class="Text" style="margin-left:.5in;text-align:left;text-indent:
-.25in;mso-list:l4 level1 lfo4">
        <![if !supportLists]>
        <span lang="X-NONE" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]>
        <span lang="X-NONE" style="font-size:11.0pt;
font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">adult patients with unresectable 
        and/or metastatic malignant gastrointestinal stromal tumours (GIST).<o:p></o:p></span></p>
    <p align="left" class="Text" style="margin-left:.5in;text-align:left;text-indent:
-.25in;mso-list:l4 level1 lfo4">
        <![if !supportLists]>
        <span lang="X-NONE" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]>
        <span lang="X-NONE" style="font-size:11.0pt;
font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">adjuvant treatment of adult 
        patients following resection of GIST. Patients who have a low or very low risk 
        of recurrence should not receive adjuvant treatment.<o:p></o:p></span></p>
    <p align="left" class="Text" style="margin-left:.5in;text-align:left;text-indent:
-.25in;mso-list:l4 level1 lfo4">
        <![if !supportLists]>
        <span lang="X-NONE" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]>
        <span lang="X-NONE" style="font-size:11.0pt;
font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">adult </span>
        <span style="font-size:11.0pt;
font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-ansi-language:EN-US">and 
        paediatric </span><span lang="X-NONE" 
            style="font-size:11.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">
        patients with newly diagnosed Philadelphia chromosome positive acute 
        lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.<o:p></o:p></span></p>
    <p align="left" class="Text" style="margin-left:.5in;text-align:left;text-indent:
-.25in;mso-list:l4 level1 lfo4">
        <![if !supportLists]>
        <span lang="X-NONE" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]>
        <span lang="X-NONE" style="font-size:11.0pt;
font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">adult patients with relapsed or 
        refractory Ph+ ALL as monotherapy.<o:p></o:p></span></p>
    <p align="left" class="Text" style="margin-left:.5in;text-align:left;text-indent:
-.25in;mso-list:l4 level1 lfo4">
        <![if !supportLists]>
        <span lang="X-NONE" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="X-NONE" 
            style="font-size:11.0pt;
font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-language:DE;layout-grid-mode:line">
        adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) 
        associated with </span>
        <span lang="X-NONE" style="font-size:11.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;
layout-grid-mode:line">platelet-derived growth factor receptor</span><span 
            lang="X-NONE" style="font-size:11.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;
mso-fareast-language:DE;layout-grid-mode:line"> (PDGFR</span><span lang="X-NONE" 
            style="font-size:11.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;layout-grid-mode:line">)
        </span>
        <span lang="X-NONE" style="font-size:11.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;
mso-fareast-language:DE;layout-grid-mode:line">gene re-arrangements.</span><span 
            lang="X-NONE" 
            style="font-size:11.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;"><o:p></o:p></span></p>
    <p align="left" class="Text" style="margin-left:.5in;text-align:left;text-indent:
-.25in;mso-list:l4 level1 lfo4">
        <![if !supportLists]>
        <span lang="X-NONE" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]>
        <span lang="X-NONE" style="font-size:11.0pt;
font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">adult patients with 
        hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) 
        with F1P1L1-PDGFRα rearrangement.<o:p></o:p></span></p>
    <p align="left" class="Text" style="margin-left:.5in;text-align:left;text-indent:
-.25in;mso-list:l4 level1 lfo4">
        <![if !supportLists]>
        <span lang="X-NONE" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]>
        <span lang="X-NONE" style="font-size:11.0pt;
font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;layout-grid-mode:line">adult 
        patients with unresectable, recurrent and/or metastatic </span>
        <span lang="X-NONE" 
            style="font-size:11.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">
        dermatofibrosarcoma protuberans (DFSP).<o:p></o:p></span></p>
    <p align="left" class="Text" style="margin-left:.5in;text-align:left;text-indent:
-.25in;mso-list:l4 level1 lfo4">
        <![if !supportLists]>
        <span lang="X-NONE" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]>
        <span lang="EN-GB" style="font-size:11.0pt;
font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-ansi-language:EN-GB;mso-fareast-language:
DE;layout-grid-mode:line">adult patients with aggressive systemic mastocytosis (ASM) 
        without the D816V c-Kit mutation or with c-Kit mutational status unknown.</span><span 
            lang="X-NONE" 
            style="font-size:11.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;"><o:p></o:p></span></p>
    <p class="MsoListParagraph">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt;mso-bidi-font-style:italic">The full registered 
        indication of </span><span style="font-size:11.0pt">Tasigna<sup>® </sup>is as 
        below: <o:p></o:p></span>
    </p>
    <ul style="margin-top:0in" type="disc">
        <li class="MsoNormal" style="mso-list:l1 level1 lfo5;text-autospace:none">
            <span style="font-size:11.0pt">newly diagnosed Philadelphia chromosome positive 
            chronic myelogenous leukaemia (CML) in the chronic phase. The effectiveness of 
            Tasigna<sup>®</sup> is based on major molecular response and cytogenetic 
            response rates. The study is ongoing and further data will be required to 
            determine long-term outcome.<o:p></o:p></span></li>
        <li class="MsoNormal" style="mso-list:l1 level1 lfo5;text-autospace:none">
            <span style="font-size:11.0pt">chronic phase and accelerated phase Philadelphia 
            chromosome positive CML with resistance or intolerance to prior therapy 
            including imatinib. Efficacy data in patients with CML in blast crisis are not 
            available. The effectiveness of Tasigna<sup>®</sup> is based on haematologic and 
            cytogenic response rates. </span>
            <span style="font-size:
     9.5pt;mso-bidi-font-weight:bold"><o:p></o:p></span></li>
    </ul>
    <p class="MsoListParagraph">
        <span style="font-size:9.5pt;mso-bidi-font-weight:
bold"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoListParagraph">
        <span style="font-size:9.5pt;mso-bidi-font-weight:
bold"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:9.5pt;mso-bidi-font-weight:bold"><o:p>&nbsp;</o:p></span></p>
    <p align="left" class="MsoBodyText2">
        <b style="mso-bidi-font-weight:normal"><u><span lang="EN-GB" 
            style="font-size:11.0pt">The Max Foundation (Max) &amp; NOA<o:p></o:p></span></u></b></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">Max is a partner in the administration of the 
        NOA. <o:p></o:p></span>
    </p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <b style="mso-bidi-font-weight:normal"><u><span style="font-size:11.0pt">The Max 
        Foundation: Background &amp; Services<o:p></o:p></span></u></b></p>
    <p class="MsoNormal">
        <b style="mso-bidi-font-weight:normal"><u><span style="font-size:11.0pt"><o:p>
        <span style="text-decoration:none">&nbsp;</span></o:p></span></u></b></p>
    <p align="left" class="MsoBodyText2">
        <span lang="EN-GB" style="font-size:11.0pt;mso-bidi-font-size:
13.5pt;color:black">The Max Foundation is a global health organization that believes 
        that all people living with cancer have the right to access the best treatment 
        and support. Through personalized access services, quality training and 
        education, and global advocacy efforts, we help people face cancer with dignity 
        and hope. </span>
        <span lang="EN-GB" style="font-size:9.0pt;mso-bidi-font-size:
11.0pt"><o:p></o:p></span>
    </p>
    <p align="left" class="MsoBodyText2">
        <span lang="EN-GB" style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p align="left" class="MsoBodyText2">
        <b style="mso-bidi-font-weight:normal"><u><span lang="EN-GB" 
            style="font-size:11.0pt">As partners in the administration of NOA, Max:<o:p></o:p></span></u></b></p>
    <p align="left" class="MsoBodyText2">
        <b style="mso-bidi-font-weight:normal"><u><span lang="EN-GB" 
            style="font-size:11.0pt"><o:p><span style="text-decoration:none">&nbsp;</span></o:p></span></u></b></p>
    <p align="left" class="MsoBodyText2">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">
        Accepts and reviews applications for NOA<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">
        Follows up on patients’ applications and re-evaluations for NOA<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2">
        <![if !supportLists]>
        <span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol"><span style="mso-list:Ignore">·<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span lang="EN-GB" style="font-size:11.0pt">
        Provides information concerning adverse events to Novartis for reporting to 
        Health Authorities as required<o:p></o:p></span></p>
    <p align="left" class="MsoBodyText2">
        <span lang="EN-GB" style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <b style="mso-bidi-font-weight:normal"><u><span style="font-size:11.0pt">
        Institutions/Physicians:<span style="mso-spacerun:yes">&nbsp; </span>Partners in 
        NOA<o:p></o:p></span></u></b></p>
    <p class="MsoNormal">
        <b style="mso-bidi-font-weight:normal"><u><span style="font-size:11.0pt"><o:p>
        <span style="text-decoration:none">&nbsp;</span></o:p></span></u></b></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">You have been identified as one of the leading 
        Institutions/Physicians in the treatment of CML, GIST and/or other rare diseases 
        in your country. As such, this document sets forth a memorandum of understanding 
        between Novartis, Max and the Institution/Physician for the administration of 
        NOA, with the goal of reaching Malaysian patients by facilitating the subsidy of 
        Glivec<sup>®</sup> and/or Tasigna<sup>®</sup> to patients who fulfill all 
        program qualifications. A desired outcome of our collaboration is to provide 
        eligible patient access to Glivec<sup>®</sup> and/or Tasigna<sup>® </sup>
        treatment following the highest quality control and safety standards.<o:p></o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt;mso-bidi-font-style:italic">Novartis </span>
        <span style="font-size:11.0pt">is responsible for <span style="color:black">
        coordinating the necessary drug logistics and distribution requirements to 
        ensure timely delivery and consistent availability of the drug supplies.<o:p></o:p></span></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">This Memorandum of Understanding hereby sets 
        forth the mutual understanding between Novartis, Max and the 
        Institution/Physician. <o:p></o:p></span>
    </p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <b style="mso-bidi-font-weight:normal"><span style="font-size:11.0pt">Max agrees 
        to:<o:p></o:p></span></b></p>
    <p class="MsoNormal">
        <b style="mso-bidi-font-weight:normal"><span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></b></p>
    <p class="MsoNormal">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
mso-fareast-font-family:Arial"><span style="mso-list:Ignore">1.0<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><u><span style="font-size:11.0pt">NOA 
        ADMINISTRATION<o:p></o:p></span></u></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">1.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Process all NOA patient applications, including performing verifications 
        of patient information submitted by the qualified physician, institution or Max 
        representative, within 5 business days of receipt of completed application and 
        all pertinent information;<o:p></o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">1.2<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Provide patient re-evaluation reminder notices in order to support NOA 
        physicians, Max representatives, and patients with timely patient re-evaluation, 
        with the goal of preventing interruption of Glivec<sup>®</sup> or Tasigna<sup>®</sup> 
        treatment unless medically prescribed;<o:p></o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">1.3<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Develop and maintain a patient tracking system available to support 
        qualified physicians for submitting patient applications to NOA, for patient 
        evaluation and approval process;<o:p></o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">1.4<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Comply with current standards regarding the protection of confidential 
        patient information and shall treat any information received from patients, Max 
        representatives and/or third party agencies or physicians, including patient 
        names and confidential medical information, as strictly confidential and shall 
        not disclose such information to any third party except its employees and 
        affiliates who need to know the same for the purpose of administering the terms 
        of this MOU;<o:p></o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">1.5<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Facilitate the reporting of Adverse Events (AE’s) as directed by 
        regulatory authorities in order to assure the highest standards of health and 
        safety for all NOA patients, as well as to facilitate Novartis in the process of 
        follow-up on the AEs reported (see also section 6.0 Adverse Event Reporting); <o:p></o:p>
        </span>
    </p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">1.6<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Facilitate communications with NOA qualified institutions and physicians 
        regarding program updates and other pertinent health and safety information to 
        facilitate the proper management of the program. <o:p></o:p></span>
    </p>
    <p align="left" class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <u><span style="font-size:11.0pt"><o:p><span style="text-decoration:none">&nbsp;</span></o:p></span></u></p>
    <p class="MsoNormal">
        <b style="mso-bidi-font-weight:normal"><u><span style="font-size:11.0pt">The 
        Institution/Physician agrees to:<o:p></o:p></span></u></b></p>
    <p class="MsoNormal">
        <b style="mso-bidi-font-weight:normal"><u><span style="font-size:11.0pt"><o:p>
        <span style="text-decoration:none">&nbsp;</span></o:p></span></u></b></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">2.0<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><u>APPLICATION &amp; APPROVAL PROCESS</u><o:p></o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">2.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>On behalf of CML, GIST and/or other rare diseases patients, complete and 
        submit the NOA application to Max . Qualified Physicians from your Institution 
        who are interested in applying for NOA on behalf of their patients can obtain an 
        application from </span><a href="http://www.maxaid.org">
        <span style="font-size:
11.0pt">www.maxaid.org</span></a><span style="font-size:11.0pt">.<span 
            style="mso-spacerun:yes">&nbsp; </span><o:p></o:p></span>
    </p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">2.2<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Once a NOA application is submitted on behalf of a patient, Max validates 
        the application and notifies the patient and physician within five days of 
        receiving all pertinent information. For every new patient, physician needs to 
        complete the application form including disease related questions;
        <b style="mso-bidi-font-weight:
normal"><o:p></o:p></b></span>
    </p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">2.3<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>To remain in the program, a patient eligibility evaluation must be filed 
        with Max at least 30 days before the current prescription expires or 60 days 
        after the last approval. <o:p></o:p></span>
    </p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <b style="mso-bidi-font-weight:normal"><span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></b></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">3.0<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;
        </span><u>PATIENT CONSENT </u><o:p></o:p></span>
    </p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">3.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><span style="color:black">The Institution/Physician will obtain the 
        written consent of the patient at the time of application to NOA, including the 
        patient’s willingness to inform about health related changes. The patient will 
        receive a copy of the signed NOA Patient consent form as provided by Novartis.<o:p></o:p></span></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">4.0<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;
        </span><u>MEDICAL PERSONNEL, DIAGNOSTIC, &amp; LABORATORY SERVICES</u><o:p></o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">4.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Institution will have licensed medical doctors who are qualified 
        hematology or cancer specialists and able to provide expert opinion on the 
        indication and the approved NOA patient’s response to therapy;<o:p></o:p></span></p>
    <p class="MsoHeader">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
mso-fareast-font-family:Arial"><span style="mso-list:Ignore">4.2<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span style="font-size:11.0pt">The 
        Institution/Physician will provide basic diagnostic and laboratory services to 
        ensure patient follow-up. The Institution/Physician will also be encouraged to 
        have the capacity to test for Philadelphia chromosome/BCR-ABL and diagnose GIST; 
        otherwise, the tests must be done by an Institution/Physician that has this 
        capacity; <o:p></o:p></span>
    </p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
mso-fareast-font-family:Arial"><span style="mso-list:Ignore">4.3<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span style="font-size:11.0pt">When the<span 
            style="mso-spacerun:yes">&nbsp; </span>Institution/Physician has the 
        capacity to test for Philadelphia chromosome/BCR-ABL and diagnose GIST, or can 
        collaborate with an Institution/Physician having this capacity, the 
        Institution/Physician will be able to serve as a referral center for patients 
        with suspicion of CML or GIST;<o:p></o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <![if !supportLists]>
        <span style="font-size:11.0pt;
mso-fareast-font-family:Arial"><span style="mso-list:Ignore">4.4<span 
            style="font:7.0pt &quot;Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></span><![endif]><span style="font-size:11.0pt">The 
        Institution/Physician agrees to allow Max or designated Max local representative 
        to provide the Institution/Physician’s contact information to patients and/or 
        caregivers for the purposes of medical referral to the Institution/Physician.<o:p></o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><span style="mso-spacerun:yes">&nbsp;</span><o:p></o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">5.0<span style="mso-tab-count:1">&nbsp; </span>
        <u>CARE OF DRUG</u><o:p></o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>5.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Institution/Physician will dispense the appropriate dose and quantity 
        to individually approved NOA patients;<o:p></o:p></span></p>
    <p class="MsoHeader">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">5.2<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Institution/Physician understands, agrees, and confirms that the drug 
        is intended to enable patients diagnosed in
        <span style="mso-bidi-font-style:italic">Malaysia,</span> for an approved 
        indication of Glivec<sup>® </sup>/ Tasigna<sup>®</sup>, to have access to Glivec<sup>®
        </sup>/ Tasigna<sup>® </sup>for the treatment of a life-threatening disease.<span 
            style="mso-spacerun:yes">&nbsp; </span>The Institution/Physician shall use 
        Glivec<sup>® </sup>/ Tasigna<sup>® </sup>only for patients approved under NOA.<o:p></o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:
11.0pt;color:black"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">6.0<span style="mso-tab-count:1">&nbsp; </span>
        <u>ADVERSE EVENT REPORTING</u><o:p></o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>6.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><span style="color:black">The Institution/Physician should report adverse 
        events as required by their national legislation;<o:p></o:p></span></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><span style="mso-tab-count:2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><o:p></o:p></span>
    </p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">6.2<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Novartis has a Novartis Drug Safety and Epidemiology Desk. The reporting 
        form shall be sent by fax to the Novartis Drug Safety and Epidemiology Desk 
        hotline number: <b style="mso-bidi-font-weight:normal">1800 806 274 (toll-free 
        fax for Malaysia)</b> or via email to mailbox:
        <b style="mso-bidi-font-weight:normal">imspvo.sgmy@novartis.com</b>;<o:p></o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">6.3<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Max will facilitate the reporting of all Adverse Events (AE’s) in order 
        to assure the highest standards of health and safety for all NOA patients, as 
        well as to meet the regulatory requirements of worldwide Health Authorities.<span 
            style="mso-spacerun:yes">&nbsp; </span>This means that Max will report to 
        Novartis all AEs that they learn of through the participation of a patient in 
        the NOA program regardless of the seriousness or suspectedness of the event.<span 
            style="mso-spacerun:yes">&nbsp; </span>This reporting is separate from the 
        local reporting obligation that physicians must adhere to based on their local 
        reporting requirements.<span style="mso-spacerun:yes">&nbsp; </span>Novartis 
        will direct all follow-up questions to the Institution/Physician<span 
            style="mso-spacerun:yes">&nbsp; </span>(including for reports received from 
        patients and/or caregivers) and will submit AE reports to Health Authorities as 
        required. As such Max<span style="mso-spacerun:yes">&nbsp; </span>will notify 
        the Institution/Physician of any adverse events reported by Novartis to the 
        Global Novartis Safety Desk and/or the local Health Authorities. <o:p></o:p>
        </span>
    </p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt;mso-bidi-font-weight:bold"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt">7.0<span style="mso-tab-count:1">&nbsp;&nbsp;
        </span><u>RECORD KEEPING</u><span style="mso-tab-count:1">&nbsp; </span><o:p></o:p>
        </span>
    </p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><span style="mso-tab-count:
1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>7.1<span 
            style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The<span 
            style="mso-spacerun:yes">&nbsp; </span>Institution/Physician shall keep 
        detailed NOA records including: the number of NOA patients using Glivec<sup>®</sup> 
        or Tasigna<sup>®</sup>, patients’ Glivec<sup>®</sup> or Tasigna<sup>® </sup>
        treatment schedule, patient’s name &amp; NOA personal ID number (PIN) (available 
        from NOA approval notification), diagnostic test results confirming approved 
        indication for Glivec<sup>®</sup> or Tasigna<sup>®</sup>, and signed NOA patient 
        consent form; <o:p></o:p></span>
    </p>
    <p class="MsoNormal">
        <a name="OLE_LINK1"><span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></a></p>
    <p class="MsoNormal">
        <span style="mso-bookmark:OLE_LINK1"><span style="font-size:11.0pt">
        <span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>7.2<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Institution/Physician shall facilitate and keep record of patient’s 
        access to NOA set forth by Novartis and outlined in this Memorandum of 
        Understanding;<span style="mso-spacerun:yes">&nbsp; </span><o:p></o:p></span>
        </span>
    </p>
    <p class="MsoNormal">
        <span style="mso-bookmark:OLE_LINK1"><span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></span></p>
    <p class="MsoNormal">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoBodyTextIndent">
        <span style="font-size:11.0pt">8.0<span style="mso-tab-count:2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><u>CONFIDENTIALITY &amp; COMMUNICATIONS<o:p></o:p></u></span></p>
    <p class="MsoBodyTextIndent">
        <span style="font-size:11.0pt">8.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Institution/Physician shall keep confidential the terms and 
        conditions of this Memorandum of Understanding (MOU); <o:p></o:p></span>
    </p>
    <p class="MsoBodyTextIndent">
        <span style="font-size:11.0pt">8.2<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Institution/Physician will comply with all local laws including the 
        protection of confidential patient information. The<span 
            style="mso-spacerun:yes">&nbsp; </span>Institution/Physician shall treat any 
        information received from the patients, including patient names and confidential 
        medical information, as strictly confidential and shall not disclose such 
        information to any third party except its employees who need to know the same 
        for the purpose of administering the terms of this MOU and<span 
            style="mso-spacerun:yes">&nbsp; </span>Max <span style="mso-spacerun:yes">&nbsp;</span>and 
        their locally appointed representatives for similar purposes;<o:p></o:p></span></p>
    <p class="MsoBodyTextIndent">
        <span style="font-size:11.0pt">8.3<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The<span style="mso-spacerun:yes">&nbsp; </span>Institution/Physician 
        shall treat any information received from Max <span style="mso-spacerun:yes">&nbsp;</span>and 
        Novartis as strictly confidential and shall not disclose such information to any 
        third party except its employees who need to know the same for the purpose of 
        administering the terms of this MOU.<o:p></o:p></span></p>
    <p class="MsoBodyTextIndent">
        <span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
    <p class="MsoNormal">
        <b><span style="font-size:11.0pt">9.0<span style="mso-tab-count:2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>OTHERS<o:p></o:p></span></b></p>
    <p class="MsoNormal">
        <b><span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></b></p>
    <p class="MsoNormal">
        <b><span style="font-size:11.0pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>9.1<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>This MOU shall be governed by Malaysian law.<o:p></o:p></span></b></p>
    <p class="MsoNormal">
        <b><span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></b></p>
    <p class="MsoNormal">
        <b><span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></b></p>
    
    <p class="MsoNormal">
        &nbsp;</p>
    <p class="MsoNormal">
        <b><span style="font-size:11.0pt"><o:p>&nbsp;</o:p></span></b></p>
    <p class="MsoNormal">
        <b><span style="font-size:11.0pt">IN WITNESS WHEREOF</span></b><span style="font-size:
11.0pt">, the parties have caused this MOU to be executed by their duly authorized 
        officers or representatives.<o:p></o:p></span></p>
   
</body>
</html>
